CLAIMS

~~1. A crystal of 4,4'-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1H-indole-1,3-diyl]dibutanoic acid having at least peaks of about 7.29, 10.24, 12.15, 17.95, and 18.44 at 2θ degree in powdered X-ray diffraction spectrum.~~

2. The crystal of 4,4'-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1H-indole-1,3-diyl]dibutanoic acid according to claim 1, having peaks of about 6.41, 7.29, 9.22, 10.03, 10.24, 12.15, 12.59, 13.36, 13.88, 14.15, 14.44, 16.60, 17.33, 17.95, 18.44, 18.86, 19.27, 20.23, 21.10, 21.85, 22.26, 23.11, 23.63, and 24.38 at 2θ degree in powdered X-ray diffraction spectrum.

3. The crystal of 4,4'-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1H-indole-1,3-diyl]dibutanoic acid according to claim 2, characterized by the chart of powdered X-ray diffraction spectrum shown in Fig. 3.

4. A crystal of 4,4'-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1H-indole-1,3-diyl]dibutanoic acid having an endothermic peak of about 157 °C in differential scanning calorimetry.

5. The crystal of 4,4'-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1H-indole-1,3-diyl]dibutanoic acid according to claim 4, characterized by the chart of differential scanning calorimetry shown in Fig. 4.

6. A crystal of 4,4'-[2-methyl-7-({4-[4-(pentafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-diyl]dibutanoic acid having at least peaks of about 5.12, ~~10.16, 10.51, 14.90, and 20.42 at 2θ degree in powdered X-~~

~~ray diffraction spectrum.~~

7. The crystal of 4,4'-[2-methyl-7-({4-[4-(pentafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-diyl]dibutanoic acid according to claim 6, having peaks of about 5.12, 8.94, 9.22, 10.16, 10.51, 12.07, 13.07, 13.62, 14.37, 14.90, 15.35, 16.05, 16.92, 17.52, 17.86, 18.61, 19.58, 19.92, 20.42, 21.19, 21.71, 22.03, 22.39, 23.74, and 24.24 at 2θ degree in powdered X-ray diffraction spectrum.

8. The crystal of 4,4'-[2-methyl-7-({4-[4-(pentafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-diyl]dibutanoic acid according to claim 7, characterized by the chart of powdered X-ray diffraction spectrum shown in Fig. 5.

9. A crystal of 4,4'-[2-methyl-7-({4-[4-(pentafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-diyl]dibutanoic acid having an endothermic peak of about 146 °C in differential scanning calorimetry.

10. The crystal of 4,4'-[2-methyl-7-({4-[4-(pentafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-diyl]dibutanoic acid according to claim 9, characterized by the chart of differential scanning calorimetry shown in Fig. 6.

11. A crystal of 4,4'-[4-fluoro-2-methyl-7-({4-[4-(2,3,4,6-tetrafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-diyl]dibutanoic acid having at least peaks of about 5.25, 12.16, 15.08, 17.07, and 21.44 at 2θ degree in powdered X-ray diffraction spectrum.

12. The crystal of 4,4'-[4-fluoro-2-methyl-7-({4-[4-(2,3,4,6-tetrafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-diyl]dibutanoic acid according to claim 11, ~~having peaks of about 5.25, 8.12, 8.92, 10.45, 11.19,~~

~~12.16, 13.12, 13.51, 14.54, 15.08, 15.65, 16.25, 17.07,~~ 17.80, 18.61, 19.59, 20.21, 20.75, 21.44, 22.23, 22.53, 23.29, and 24.41 at 2θ degree in powdered X-ray diffraction spectrum.

13. The crystal of 4,4'-[4-fluoro-2-methyl-7-({4-[4-(2,3,4,6-tetrafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-diyl]dibutanoic acid according to claim 12, characterized by the chart of powdered X-ray diffraction spectrum shown in Fig. 9.

14. A crystal of 4,4'-[4-fluoro-2-methyl-7-({4-[4-(2,3,4,6-tetrafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-diyl]dibutanoic acid having an endothermic peak of about 152 °C in differential scanning calorimetry.

15. The crystal of 4,4'-[4-fluoro-2-methyl-7-({4-[4-(2,3,4,6-tetrafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-diyl]dibutanoic acid according to claim 14, characterized by the chart of differential scanning calorimetry shown in Fig. 10.

16. A pharmaceutical composition containing the crystal of 4,4'-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1H-indole-1,3-diyl]dibutanoic acid according to any one of claims 1 to 5 as an active ingredient.

17. A pharmaceutical composition containing the crystal of 4,4'-[2-methyl-7-({4-[4-(pentafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-diyl]dibutanoic acid according to any one of claims 6 to 10 as an active ingredient.

18. A pharmaceutical composition containing the crystal of 4,4'-[4-fluoro-2-methyl-7-({4-[4-(2,3,4,6-~~tetrafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-~~

~~diyl]dibutanoic acid according to any one of claims 11 to~~ 15 as an active ingredient.

19. A compound selected from the group consisting of

(1) 4,4'-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1H-indole-1,3-diyl]dibutanoic acid,

(2) 4,4'-[2-methyl-7-({4-[4-(pentafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-diyl]dibutanoic acid and

(3) 4,4'-[4-fluoro-2-methyl-7-({4-[4-(2,3,4,6-tetrafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-diyl]dibutanoic acid,

or a salt or a solvate thereof.

20. The compound according to claim 19, wherein the compound is 4,4'-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1H-indole-1,3-diyl]dibutanoic acid.

21. The compound according to claim 19, wherein the compound is 4,4'-[2-methyl-7-({4-[4-(pentafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-diyl]dibutanoic acid.

22. The compound according to claim 19, wherein the compound is 4,4'-[4-fluoro-2-methyl-7-({4-[4-(2,3,4,6-tetrafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-diyl]dibutanoic acid.

23. A pharmaceutical composition comprising the compound, or a salt or a solvate thereof according to claim 19 as an ~~active ingredient.~~

Replaced by New claims 1 to 23.

CLAIMS

1. A crystal of 4,4'-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1H-indole-1,3-diyl]dibutanoic acid having at least peaks of about 7.29, 10.24, 12.15, 17.95, and 18.44 at 2θ degree in powdered X-ray diffraction spectrum.

2. The crystal of 4,4'-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1H-indole-1,3-diyl]dibutanoic acid according to claim 1, having peaks of about 6.41, 7.29, 9.22, 10.03, 10.24, 12.15, 12.59, 13.36, 13.88, 14.15, 14.44, 16.60, 17.33, 17.95, 18.44, 18.86, 19.27, 20.23, 21.10, 21.85, 22.26, 23.11, 23.63, and 24.38 at 2θ degree in powdered X-ray diffraction spectrum.

3. The crystal of 4,4'-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1H-indole-1,3-diyl]dibutanoic acid according to claim 2, characterized by the chart of powdered X-ray diffraction spectrum shown in Fig. 3.

4. A crystal of 4,4'-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1H-indole-1,3-diyl]dibutanoic acid having an endothermic peak of about 157 °C in differential scanning calorimetry.

5. The crystal of 4,4'-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1H-indole-1,3-diyl]dibutanoic acid according to claim 4, characterized by the chart of differential scanning calorimetry shown in Fig. 4.

6. A crystal of 4,4'-[2-methyl-7-({4-[4-(pentafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-diyl]dibutanoic acid having at least peaks of about 5.12, 10.16, 10.51, 14.90, and 20.42 at 2θ degree in powdered X-ray diffraction spectrum.

7. The crystal of 4,4'-[2-methyl-7-({4-[4-(pentafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-diyl]dibutanoic acid according to claim 6, having peaks of about 5.12, 8.94, 9.22, 10.16, 10.51, 12.07, 13.07, 13.62, 14.37, 14.90, 15.35, 16.05, 16.92, 17.52, 17.86, 18.61, 19.58, 19.92, 20.42, 21.19, 21.71, 22.03, 22.39, 23.74, and 24.24 at 2θ degree in powdered X-ray diffraction spectrum.

8. The crystal of 4,4'-[2-methyl-7-({4-[4-(pentafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-diyl]dibutanoic acid according to claim 7, characterized by the chart of powdered X-ray diffraction spectrum shown in Fig. 5.

9. A crystal of 4,4'-[2-methyl-7-({4-[4-(pentafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-diyl]dibutanoic acid having an endothermic peak of about 146 °C in differential scanning calorimetry.

10. The crystal of 4,4'-[2-methyl-7-({4-[4-(pentafluorophenyl)butoxy]phenyl}ethynyl)-

1H-indole-1,3-diyl]dibutanoic acid according to claim 9, characterized by the chart of differential scanning calorimetry shown in Fig. 6.

11. A crystal of 4,4'-[4-fluoro-2-methyl-7-({4-[4-(2,3,4,6-tetrafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-diyl]dibutanoic acid having at least peaks of about 5.25, 12.16, 15.08, 17.07, and 21.44 at 2θ degree in powdered X-ray diffraction spectrum.

12. The crystal of 4,4'-[4-fluoro-2-methyl-7-({4-[4-(2,3,4,6-tetrafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-diyl]dibutanoic acid according to claim 11, having peaks of about 5.25, 8.12, 8.92, 10.45, 11.19, 12.16, 13.12, 13.51, 14.54, 15.08, 15.65, 16.25, 17.07, 17.80, 18.61, 19.59, 20.21, 20.75, 21.44, 22.23, 22.53, 23.29, and 24.41 at 2θ degree in powdered X-ray diffraction spectrum.

13. The crystal of 4,4'-[4-fluoro-2-methyl-7-({4-[4-(2,3,4,6-tetrafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-diyl]dibutanoic acid according to claim 12, characterized by the chart of powdered X-ray diffraction spectrum shown in Fig. 9.

14. A crystal of 4,4'-[4-fluoro-2-methyl-7-({4-[4-(2,3,4,6-tetrafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-diyl]dibutanoic acid having an endothermic peak of about 152 °C in differential scanning calorimetry.

15. The crystal of 4,4'-[4-fluoro-2-methyl-7-({4-[4-(2,3,4,6-tetrafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-diyl]dibutanoic acid according to claim 14, characterized by the chart of differential scanning calorimetry shown in Fig. 10.

16. A pharmaceutical composition containing the crystal of 4,4'-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1H-indole-1,3-diyl]dibutanoic acid according to any one of claims 1 to 5 as the active ingredient thereof.

17. A pharmaceutical composition containing the crystal of 4,4'-[2-methyl-7-({4-[4-(pentafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-diyl]dibutanoic acid according to any one of claims 6 to 10 as the active ingredient thereof.

18. A pharmaceutical composition containing the crystal of 4,4'-[4-fluoro-2-methyl-7-({4-[4-(2,3,4,6-tetrafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-diyl]dibutanoic acid according to any one of claims 11 to 15 as the active ingredient thereof.

19. A compound selected from the group consisting of

(1) 4,4'-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1H-indole-1,3-diyl]dibutanoic acid,

(2) 4,4'-[2-methyl-7-({4-[4-(pentafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-diyl]dibutanoic acid and

(3) 4,4'-[4-fluoro-2-methyl-7-({4-[4-(2,3,4,6-tetrafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-diyl]dibutanoic acid,

or a salt or a solvate thereof.

20. The compound according to claim 19, wherein the compound is 4,4'-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl}ethynyl)-2-methyl-1H-indole-1,3-diyl]dibutanoic acid.

21. The compound according to claim 19, wherein the compound is 4,4'-[2-methyl-7-({4-[4-(pentafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-diyl]dibutanoic acid.

22. The compound according to claim 19, wherein the compound is 4,4'-[4-fluoro-2-methyl-7-({4-[4-(2,3,4,6-tetrafluorophenyl)butoxy]phenyl}ethynyl)-1H-indole-1,3-diyl]dibutanoic acid.

23. A pharmaceutical composition comprising the compound, or a salt or a solvate thereof according to claim 19 as the active ingredient thereof.